| Literature DB >> 27462508 |
Phatthanaphong Therdtatha1, Chanabhorn Tandumrongpong2, Komkhae Pilasombut3, Hiromi Matsusaki4, Suttipun Keawsompong1, Sunee Nitisinprasert1.
Abstract
Lactobacillus salivarius KL-D4 isolated from duck intestine produced bacteriocin which was stable at high temperature and a wide pH range of 3-10. Its cell free supernatant at pH 5.5 exhibited wide inhibitory spectrum against both G+ and G- bacteria. The highest bacteriocin production was obtained in MRS broth supplemented with 0.5 % (w/v) CaCO3 at 6 h by gentle shaking. PCR walking using specific primers at the conserved region of class-II bacteriocin resulted in 4 known genes of kld1, kld2, kld3 and kld4 with 100 % similarity to genes encoding for salivaricin α, β, induction peptide and histidine protein kinase of Lb. salivarius GJ-24 which did not previously report for bacteriocin characterization, while showing 94, 93, 59 and 62 % to other salivaricin gene cluster, respectively. The high activities of 25,600 AU/ml indicated a strong induction peptide expressed by kld3 which has low similarity to previous inducer reported. Based on operon analysis, only kld1, kld3 and kld4 could be expressed and subsequently elucidated that only salivaricin α like bacteriocin was produced and secreted out of the cells. Using protein purification, only a single peptide band obtained showed that this strain produced one bacteriocin which could be salivaricin α namely salivaricin KLD showing about 4.3 kDa on SDS-PAGE. Partial purification by 20 % ammonium sulfate precipitation of the product was tested on the artificial contamination of creamy filling by Bacillus cereus, Enterococcus faecalis, Pseudomonas stutzeri, Staphylococcus sp. and Stenotrophomonas sp. resulting the growth inhibitory efficiency of 4.45-66.9, 11.5-100, 100, 0-28.1 and 5-100 % respectively. Therefore, salivaricin KLD can be a tentative biopreservative for food industry in the future.Entities:
Keywords: Bakery products; Biopreservative; Creamy filling; Lactobacillus salivarius; Salivaricin
Year: 2016 PMID: 27462508 PMCID: PMC4942445 DOI: 10.1186/s40064-016-2693-4
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
List of target bacterial strains and their cultivation conditions
| Indicator strain | Media | Temperature (°C) |
|---|---|---|
| Lactic acid bacteria | ||
| | MRS | 30 |
| | MRS | 30 |
| | MRS | 30 |
| | MRS | 30 |
| | MRS | 30 |
| | MRS | 30 |
| | NB | 37 |
| | NB | 37 |
| Other Gram-positive bacteria | ||
| | NB | 37 |
| | TSBYE | 37 |
| | TSBYE | 37 |
| | TSBYE | 25 |
| | TSBYE | 37 |
| | NB | 37 |
| | NB | 37 |
| | NB | 30 |
| Gram-negative bacteria | ||
| | NB | 30 |
| | NB | 37 |
| | TSBYE | 25 |
| | TSBYE | 25 |
| | NB | 37 |
| | NB | 37 |
| | NB | 37 |
ATCC American Type Culture Collection, Rockville, Md; DMST Department of Medical Science Thailand, Thailand; JCM Japanese Culture of Microorganism, Wako, Japan; NBRC National Institute of Technology and Evaluation (NITE) Biological Resource Center; TISTR Thailand Institute of Scientific and Technological Research; KUB Department of Biotechnology, Kasetsart University, Thailand
List of primers and nucleotide sequences
| Primer set | Sequence 5′–3′ | Purpose |
|---|---|---|
| SalAα-f1 | 5′-ATGAAGGAATTTACAGTATTGACAGAATGT-3′ | To amplify |
| SalAα-r1 | 5′-TTATAAACAAGTAAGCGCTCCGCCTACCAT-3′ | |
| D4-f1 | 5′-GCTGGTATTGTAGGCGGAGCAAACTTAGGA-3′ | To amplify |
| Oligo105 | 5′-CYTCDATNGCRTTRTC-3′* | |
| D4-f1 | 5′-GCTGGTATTGTAGGCGGAGCAAACTTAGGA-3′ | To amplify |
| D4-r1 | 5′-CTACACAATTAGGATAACGTTTCCCACCGT-3 | |
| D4-f2 | 5′-GATTAAGACATTCAAATCAAGATATTTGTA-3′ | To confirm |
| D4-r2 | 5′-ATGTAACGACTATAAATACAATATTTTGTT-3′ | |
| T7 promoter | 5′-TAATACGACTCACTATAGGG-3′ | Colony PCR for pT7Blue-T vector |
| U-19mer | 5′-GTTTTCCCAGTCACGACGT-3′ | |
| M13RV | 5′-CAGGAAACAGCTATGAC-3′ | Colony PCR for pMD20-T vector |
| M13M4 | 5′-GTTTTCCCAGTCACGAC-3′ |
* D = A, G, T; R = A, G; Y = C, T
Inhibitory activities against Lactobacillus sakei subsp. sakei jcm1157T of cell free supernatant under various conditions
| Treatment | Activity (AU/ml) |
|---|---|
| Enzymatic stability | |
| Control | 12,800 |
| Protenase K pH 8.0 | 0 |
| Pepsin pH 3.0 | 0 |
| Trypsin pH 8.5 | 0 |
| α-chymotrypsin pH 8.5 | 0 |
| Actinase E pH 7.0 | 0 |
| α-amylase pH 7.0 | 12,800 |
| Lipase pH 7.0 | 12,800 |
| Heat stability | |
| 100 °C for 5 min, pH 5.5 | 25,600 |
| 100 °C for 30 min, pH 5.5 | 25,600 |
| 121 °C for 15 min, pH 5.5 | 25,600 |
| pH stability | |
| pH 3.0 | 12,800 |
| pH 4.0 | 12,800 |
| pH 5.0 | 12,800 |
| pH 5.5 | 25,600 |
| pH 6.0 | 25,600 |
| pH 7.0 | 25,600 |
| pH 8.0 | 12,800 |
| pH 9.0 | 12,800 |
| pH 10.0 | 12,800 |
Fig. 1Growth and bacteriocin production by Lb. salivarius KL-D4 in MRS broth. Static condition (a); shaking condition with 120 rpm (b); supplementation with CaCo3, solid line; with out CaCo3, dash line; pH during fermentation, (triangle); viable cells determined by standard plate count method, (black circle); black bars and white ones are antibacterial activities from culture grown in MRS supplement with and without CaCO3, respectively
Specific growth rate of bacteriocin producing Lb. salivarius KL-D4 grown in MRS medium with and without CaCO3 at 37° C under static and shaking condition
| Condition | Specific growth rate (μ) |
|---|---|
| Static condition (ST) | 0.09 ± 0.01 |
| Static condition with 0.5 % (w/v) of CaCO3 (ST + Ca) | 0.08 ± 0.01 |
| Shaking at 120 rpm (SK) | 0.06 ± 0.00 |
| Shaking at 120 rpm with 0.5 % (w/v) of CaCO3 (SK + Ca) | 0.04 ± 0.00 |
Inhibitory activities of cell free supernatant and partial purified salivaricin KLD against various target strains
| Indicator strain | Inhibitory activity (AU/ml) |
|---|---|
| Lactic acid bacteria1 | |
| | 800 |
| | 200 |
| | 25,600 |
| | 100 |
| | 400 |
| | 800 |
| Other Gram-positive bacteria1 | |
| | 3200 |
| | 100 |
| | 0 |
| | 0 |
| | 6400 |
| | 0 |
| Gram-negative bacteria1 | |
| | 0 |
| | 0 |
| | 800 |
| | 800 |
| | 0 |
| Bacterial contaminants from Éclair product2 | |
| | 12,800 |
| | 12,800 |
| | 800 |
| | 3200 |
| | 1600 |
| | 0 |
The strain KUB-E1, -E2, -E5, -E6, -E7 and -E8 isolated from éclair production process and deposited in theculture collection of the Specialized Research Unit: Probiotics and Prebiotics for Health, Department of Biotechnology, Kasetsart University, Thailand
ATCC American Type Culture Collection, Rockville, Md; DMST Department of Medical Science Thailand, Thailand; JCM Japanese Culture of Microorganism, Wako, Japan; NBRC National Institute of Technology and Evaluation (NITE) Biological Resource Center; TISTR Thailand Institute of Scientific and Technological Research
aActivities determination of CFS
bActivities determination of KLD
Fig. 2Nucleotide sequence and deduced protein in the kld locus. The putative promoter sequences are underlined; the ribosomal binding sites (RBS) are boxed and underlined. Nucleotide sequences alignment was performed using the GENETYX-MAC software (GENETYX®, Japan) on September 28th, 2012. Bacterial promoter prediction was performed using BROM on the Softberry (online program) on August 4th, 2015
Purification table of salivaricin KLD
| Purification stage | Vol. (ml) | Activity (AU/ml) | Protein concentration (mg/ml) | Total protein (mg) | Total activity (AU) | Specific activity (AU/mg) | Purification (folds) | Yield (%) |
|---|---|---|---|---|---|---|---|---|
| Cell free supernatant | 1000 | 25,600 | 18.600 | 18,600.000 | 2.56 × 107 | 1.38 × 103 | 1 | 100 |
| (NH4)2SO4 precipitate | 20 | 102,400 | 2.150 | 43.000 | 2.05 × 106 | 4.77 × 104 | 34.57 | 8.01 |
| Cation exchange | 20 | 12,800 | 0.224 | 4.480 | 2.56 × 105 | 5.71 × 104 | 41.38 | 1.00 |
| RP-HPLC | 1 | 3200 | 0.057 | 0.057 | 3.20 × 103 | 5.61 × 104 | 40.68 | 0.01 |
All % yield values are expressed in terms of activity units in the cell free supernatant taken as 100 % while purification values are in the terms of specific activities in the cell free supernatant taken as 1
Fig. 3Reverse-phase chromatogram of the salivaricin KLD. The target fraction (a salivaricin KLD fraction) was earned by eluting with 74 % of solvent B. Dash line is a gradient condition of solvent B (acetonitrile, %v/v)
Fig. 4Characterization of purified salivaricin KLD. Silver stained Tris–Tricine SDS-PAGE containing 15.0 % polyacrylamide gel (a), Protein with antibacterial activity visualized by overlaying soft MRS agar containing cells of Lb. sakei subsp. sakei JCM 1157T (b); lane 1 Spectra Multicolor Low Range Protein Ladder (Thermo Scientific Pierce, USA); lane 2: purified salivaricin KLD. The arrows indicate a salivaricin KLD fraction and its activity
Growth inhibitory efficiency of antimicrobial substances against bacterial contaminants in sterilized creamy filling containing about 5 log CFU/g of each target strain and various food preservatives of PP-KLD, H-3 and glycine
| Target strain | Treatment | Growth inhibitory efficiency (%)b | |
|---|---|---|---|
| 0 h | 72 h | ||
|
| 1 %PP-KLD | 22.76 ± 0.82b | 52.27 ± 2.09b |
| 5 %PP-KLD | 39.30 ± 3.08c | 100.00 ± 0.00c | |
| 10 %PP-KLD | 26.46 ± 0.40b | 100.00 ± 0.00c | |
| 1 %H-3 | 0.39 ± 0.16a | 1.75 ± 0.27a | |
| 2 %Glycine | 1.27 ± 0.32a | 1.87 ± 0.45a | |
|
| 1 %PP-KLD | 15.40 ± 3.14b | 11.51 ± 5.34b |
| 5 %PP-KLD | 17.83 ± 2.43b | 30.69 ± 0.28c | |
| 10 %PP-KLD | 19.96 ± 0.94b | 60.12 ± 0.4d | |
| 1 %PP-H-3 | 1.88 ± 0.08a | 0.90 ± 0.13a | |
| 2 %PP-Glycine | 3.61 ± 0.39a | 3.89 ± 0.15a | |
|
| 1 %KLD | 1.83 ± 1.02b | 0.00 ± 0.00a |
| 5 %KLD | 0.46 ± 2.36a | 0.00 ± 0.00a | |
| 10 %KLD | 1.80 ± 2.55b | 0.00 ± 0.00a | |
| 1 %H-3 | 3.24 ± 0.38c | 24.58 ± 1.11b | |
| 2 %Glycine | 0.00 ± 0.00a | 22.37 ± 1.14b | |
|
| 1 %PP-KLD | 1.96 ± 1.95a | 22.91 ± 0.23a |
| 5 %PP-KLD | 3.85 ± 2.66a | 28.10 ± 1.38c | |
| 10 %PP-KLD | 3.37 ± 0.17a | 25.80 ± 1.85c | |
| 1 %H-3 | 2.58 ± 0.18a | 23.05 ± 0.28ab | |
| 2 %Glycine | 10.54 ± 0.27b | 25.69 ± 0.28bc | |
|
| 1 %PP-KLD | 2.02 ± 1.43a | 4.47 ± 2.43a |
| 5 %PP-KLD | 6.18 ± 0.41b | 50.39 ± 1.58b | |
| 10 %PP-KLD | 10.14 ± 0.29c | 66.94 ± 0.88c | |
| 1 %H-3 | 3.28 ± 0.19a | 44.29 ± 0.29b | |
| 2 %Glycine | 8.85 ± 0.22c | 6.97 ± 0.17a | |
|
| 1 %PP-KLD | 3.92 ± 5.93a | 100.00 ± 0.00c |
| 5 %PP-KLD | 100.00 ± 0.00c | 100.00 ± 0.00c | |
| 10 %PP-KLD | 100.00 ± 0.00c | 100.00 ± 0.00c | |
| 1 %H-3 | 11.35 ± 1.15b | 12.53 ± 0.58a | |
| 2 %Glycine | 14.96 ± 0.31b | 64.07 ± 2.34b | |
|
| 1 %PP-KLD | 0.27 ± 0.16a | 5.25 ± 2.56a |
| 5 %PP-KLD | 0.00 ± 0.00a | 100.00 ± 0.00d | |
| 10 %PP-KLD | 1.50 ± 0.40b | 100.00 ± 0.00d | |
| 1 %H-3 | 5.82 ± 0.05c | 9.04 ± 0.36b | |
| 2 %Glycine | 6.24 ± 0.54c | 44.84 ± 1.44c | |
All growth efficiency obtained are a mean of two replications ± SD (SD); a–d, means in the same column of each target strain with different lower case letters are significantly different (P < 0.05)
aFive treatments of antimicrobial substance PP-KLD at the concentrations of 1, 5 and 10 %, 1 % H3 and 2 % glycine tested
bGrowth inhibitory efficiency defined as percentage of survival cells after antimicrobial substance treatment compared to the control mentioned elsewhere